Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/31061

Title:	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Authors:	Pascual, Tomas Apellániz-Ruiz, María Pernaut, Cristina Cueto-Felgueroso, Cecilia Villalba, Pablo Álvarez, Carlos Manso, Luis Inglada-Pérez, Lucia Robledo, Mercedes Rodríguez-Antona, Cristina Ciruelos, Eva View more
Mesh:	Adult Aged Antineoplastic Agents Breast Neoplasms Disease-Free Survival Everolimus Female Genotype Humans Middle Aged Pharmacogenetics Prognosis Survival Rate Treatment Outcome Polymorphism, Single Nucleotide View more
Issue Date:	2017
Citation:	PLoS ONE.2017;(12)7:e0180192
Abstract:	Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there is great inter-patient variability in toxicity and response to exemestane-everolimus treatment. The objective of this study was to perform an exploratory study analyzing the implication of single nucleotide polymorphisms (SNPs) on outcomes from this treatment through a pharmacogenetic analysis.
PMID:	28727815
URI:	https://hdl.handle.net/20.500.12530/31061
Rights:	openAccess
Appears in Collections:	Hospitales > H. U. 12 de Octubre > Artículos

Files in This Item:

File	Description	Size	Format
PMC5519037.pdf		1.59 MB	Adobe PDF	View/Open